The FDA flagged at least five cases of severe or very severe RSV lower respiratory tract infections in infants immunized with ...

China's Zhifei will pay GSK about 2.3 billion pounds ($2.9 billion) for the exclusive rights to distribute GSK's shingles ...

Learn about this vaccine that protects against a common seasonal virus that can sometimes cause severe disease, with info on ...

GSK said on Thursday it had expanded its agreement with China's largest vaccine company Zhifei to explore a potential ...

GSK plc stock is downgraded due to litigation risks, weak sales, and market pressures, dividend yield remains a bright spot. Click for more on GSK stock.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/91.DyCR3BqR.js ...

Although the FDA has expanded approvals for two respiratory syncytial virus (RSV) vaccines to include high-risk young and ...

Under the revised agreement, the two have taken their RSV commitment a step forward as Zhifei agrees to engage exclusively ...

GSK said in a statement that it is confident that it will be able to launch Arexvy in time for the 2023/24 RSV season, describing the new vaccine as a “turning point” in efforts to reduce the ...

Physicians in PA don’t expect to see the surges they saw during the first winters of the COVID-19 pandemic, but encouraged ...

GSK revises deal with Chongqing Zhifei Biological Products, extending Shingrix distribution rights in China through 2034 but ...

Fiona P. Havers, MD, MHS, spoke with Physician’s Weekly about managing RSV as a newly vaccine-preventable disease now that ...